Processa Pharmaceuticals (NASDAQ:PCSA) Publishes Investor Presentation
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) filed a Form 8-K with the United States Securities and Exchange Commission (SEC). In this filing, Processa Pharmaceuticals disclosed that a copy of a slide ...
Metastatic Colorectal Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight
DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...
Processa Pharmaceuticals faces Nasdaq delisting risk over share price
Processa Pharmaceuticals , Inc. (NASDAQ:PCSA), currently trading at $0.63 with a market capitalization of just $2.95 million, has been notified by Nasdaq's Listing Qualifications Department that its ...
Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on ...
Favourable Signals For Processa Pharmaceuticals: Numerous Insiders Acquired Stock
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying ...
Wall Street Journal15d
Processa Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...